These data, which are from the OTEMTO® 1&2 clinical studies, show a clinically meaningful improvement in health-related quality of life, as measured by the St. George's Respiratory Questionnaire (SGRQ ...

Propeller Health and Boehringer Ingelheim announced a new commercial partnership. Under the partnership, COPD and asthma patients using Boehringer's Respimat inhaler will have the opportunity to ...

The program automatically reduces the cost of the inhaler at the pharmacy for eligible patients with commercial insurance. Out-of-pocket costs for Boehringer Ingelheim asthma and chronic obstructive ...

Please provide your email address to receive an email when new articles are posted on . Several clinicians expressed concern about inhaler costs for those with COPD in January. AstraZeneca, Boehringer ...

The FINANCIAL — Boehringer Ingelheim will present new data from its broad respiratory portfolio, which includes recently approved Spiolto Respimat (tiotropium ...

Propeller has been working with Boehringer Ingelheim for about a year. Last fall they announced the partnership at Health 2.0, including a pilot of the Respimat sensor that just received clearance.

This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated. (The Hill) — Drugmaker Boehringer Ingelheim ...

(BPT) – For many patients, a diagnosis of chronic obstructive pulmonary disease (COPD) can come as a shock. COPD, a chronic respiratory condition, can drastically impact quality of life, making ...